NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced that Robert Goodman, M.D., has been named to iCAD’s Board of Directors. Dr. Goodman brings nearly 50 years of clinical experience, along with extensive academic and leadership credentials. He is the first radiation oncologist to serve on iCAD’s multidisciplinary Board.
“Dr. Goodman’s impressive clinical background, coupled with his business leadership experience and prestigious academic affiliations, will make him an invaluable addition to iCAD’s Board of Directors,” said Ken Ferry, Chief Executive Officer of iCAD, Inc. “As a highly regarded member of the radiation oncology community, we look forward to Dr. Goodman’s guidance and insight as we continue to grow and strengthen the Xoft business.”
Dr. Goodman is a renowned radiation oncologist who is credited with pioneering the use of radiotherapy to treat women with breast cancer. He has served as the Pancoast Professor and Chair of the Department of Radiation Oncology at the University of Pennsylvania and Chair of Radiation Oncology at St. Barnabas Medical Center. Additionally, he served two years as Acting Executive Director of the Hospital of the University of Pennsylvania. Dr. Goodman has also held faculty appointments at several prestigious medical schools including Harvard Medical School and University of Pennsylvania School of Medicine. He has also led Radiation Therapy Resident Programs at the University of Pennsylvania and Allegheny University Hospitals.
“Electronic Brachytherapy is quickly becoming a sought after treatment option in the field of radiation oncology,” said Dr. Goodman. “The Xoft System’s mobile capabilities and innovative delivery technology help address some of the most challenging issues associated with comprehensive cancer care in today’s clinical environment. I look forward to joining iCAD’s esteemed board members in their commitment to improving upon and expanding the availability of advanced treatment options that play such a critical role in the lives of cancer patients.”
Dr. Goodman has been published extensively in highly respected peer-reviewed journals and has been recognized by Castle-Connolly, Good Housekeeping and Redbook as one of the top physicians in America. He has also consistently been named as a “Top Doctor” by New York Magazine, New Jersey Monthly and New Jersey Life, among other publications.
Dr. Goodman is a Phi Beta Kappa graduate of Dartmouth College and received his medical degree from the College of Physicians and Surgeons of Columbia University. He trained in Internal Medicine and Radiation Oncology at Harvard University and is triple-boarded in Internal Medicine, Medical Oncology and Radiation Oncology.
About iCAD, Inc.
iCAD is an industry-leading provider of Computer-Aided Detection (CAD) technologies, advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of Intraoperative Radiation Therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers. For more information, call (877) iCADnow, or visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov